Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Reports Decreased Q2 Revenues

NEW YORK, Aug. 5 (GenomeWeb News) - Transgenomic today reported decreased second-quarter revenues amid widened net losses.

 

The Omaha, Neb. company had revenues of $8.5 million for the quarter, compared to $9.4 million for the same period last year.

 

Losses totalled $4.7 million, compared to $4.0 million for the year-ago quarter.

 

R&D expenses decreased also, to $2.4 million, from $3.0 million in the same period last year.

 

As of June 30, the company had cash, cash equivalents, and short-term investments of $3.0 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more